دورية أكاديمية
The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?
| العنوان: | The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis? |
|---|---|
| المؤلفون: | Scott W. Canna, Fabrizio De Benedetti |
| المصدر: | Pediatric Rheumatology Online Journal, Vol 21, Iss S1, Pp 1-6 (2024) |
| بيانات النشر: | BMC, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Pediatrics LCC:Diseases of the musculoskeletal system |
| مصطلحات موضوعية: | IL-18, IL-18 blocker, Refractory SJIA, Biomarker driven trials, IL-18ophathies, Inflammasopathies, Pediatrics, RJ1-570, Diseases of the musculoskeletal system, RC925-935 |
| الوصف: | Abstract Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, there was broad agreement on the conclusion that IL-18 is a uniquely specific biomarker for many of the subsets of SJIA most in need of new therapies, and it may define a class of diseases mediated by IL-18 excess. The consensus was that leveraging IL-18 remains our most promising “lead” for use in refractory SJIA as it may mechanistically explain the disease pathophysiology and lead to more targeted therapies. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1546-0096 |
| Relation: | https://doaj.org/toc/1546-0096 |
| DOI: | 10.1186/s12969-023-00867-y |
| URL الوصول: | https://doaj.org/article/537d6e32416e48f980b48ea3ec208ea9 |
| رقم الأكسشن: | edsdoj.537d6e32416e48f980b48ea3ec208ea9 |
| قاعدة البيانات: | Directory of Open Access Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 15460096 |
|---|---|
| DOI: | 10.1186/s12969-023-00867-y |